journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/28709937/detection-of-lung-cancer-and-egfr-mutation-by-electronic-nose-system
#1
Dekel Shlomi, Manal Abud, Ori Liran, Jair Bar, Naomi Gai-Mor, Maya Ilouze, Amir Onn, Alon Ben-Nun, Hossam Haick, Nir Peled
BACKGROUND: Early detection of lung cancer (LC) has been well established as a significant key point in patient survival and prognosis. New highly sensitive nanoarray sensors for exhaled Volatile Organic Compounds (VOCs) have been developed and coupled with powerful statistical programs may be used when diseases such as LC are suspected. Detection of genetic aberration mutation by nanoarray sensors is the next target. METHODS: Breath samples were taken from patients who were evaluated for suspicious pulmonary lesions...
July 11, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28694035/assessment-of-the-itmig-statement-on-the-who-histological-classification-and-of-the-8th-tnm-staging-of-thymic-epithelial-tumors-of-a-series-of-188-thymic-epithelial-tumors
#2
Alexandra Meurgey, Nicolas Girard, Claire Merveilleux du Vignaux, Jean-Michel Maury, François Tronc, Françoise Thivolet-Bejui, Lara Chalabreysse
BACKGROUND: Thymic epithelial tumors (TETs) are rare intrathoracic malignancies which are categorized histologically according to the World Health Organization (WHO) classification, recently updated in 2015 based on a consensus statement of ITMIG; at the same time, the standard Masaoka-Koga staging system is intended to be replaced by the 8th edition of the TNM staging classification by the American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) consortium...
July 7, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28689043/pooled-systemic-efficacy-and-safety-data-from-the-pivotal-phase-ii-studies-np28673-and-np28761-of-alectinib-in-alk-positive-non-small-cell-lung-cancer
#3
James Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, Shirish Gadgeel, Leena Gandhi, Dong-Wan Kim, Fabrice Barlesi, Ramaswamy Govindan, Anne-Marie C Dingemans, Lucio Crino, Herve Lena, Sanjay Popat, Jin Seok Ahn, Eric Dansin, Sophie Golding, Walter Bordogna, Bogdana Balas, Peter N Morcos, Ali Zeaiter, Alice T Shaw
INTRODUCTION: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report pooled efficacy and safety data after 15 and 18 months' longer follow-up than the respective primary analyses. MATERIALS AND METHODS: Enrolled patients had ALK-positive NSCLC and had progressed on, or were intolerant to, crizotinib. Patients received oral alectinib 600 mg twice daily. The primary endpoint in both studies was objective response rate (ORR) assessed by an independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST v1...
July 5, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28662863/brief-report-lung-adenocarcinoma-harboring-egfr-t790m-and-in-trans-c797s-responds-to-combination-therapy-of-first-and-third-generation-egfr-tkis-and-shifts-allelic-configuration-at-resistance
#4
Zhen Wang, Jin-Ji Yang, Jie Huang, Jun-Yi Ye, Xu-Chao Zhang, Hai-Yan Tu, Han Han-Zhang, Yi-Long Wu
INTRODUCTION: The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S. In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first and third generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, this has not been reported clinically. METHODS: We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from an advanced lung adenocarcinoma patient undergoing targeted therapy...
June 26, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28648948/randomized-phase-ii-study-comparing-prophylactic-cranial-irradiation-alone-to-prophylactic-cranial-irradiation-and-consolidative-extra-cranial-irradiation-for-extensive-disease-small-cell-lung-cancer-ed-sclc-nrg-oncology-rtog-0937
#5
Elizabeth M Gore, Chen Hu, Alexander Y Sun, Daniel F Grimm, Suresh S Ramalingam, Neal E Dunlap, Kristin A Higgins, Maria Werner-Wasik, Aaron M Allen, Puneeth Iyengar, Gregory M M Videtic, Russell K Hales, Ronald C McGarry, James J Urbanic, Anthony T Pu, Candice A Johnstone, Volker W Stieber, Rebecca Paulus, Jeffrey D Bradley
INTRODUCTION: RTOG-0937 is a randomized phase-II trial evaluating 1-year OS with PCI or PCI plus consolidative radiation therapy (cRT) to intra-thoracic disease and extracranial metastases for ED-SCLC. METHODS: Patients with 1-4 extracranial metastases were eligible after CR or PR to chemotherapy. Randomization was to PCI or PCI+cRT to the thorax and metastases. Original stratification included PR vs CR after chemotherapy and 1 vs 2-4 metastases; age < 65 vs > 65 was added after an observed imbalance...
June 22, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28647672/therapeutic-targeting-of-nuclear-export-inhibition-in-lung-cancer
#6
Arjun Gupta, Jessica M Saltarski, Michael A White, Pier P Scaglioni, David E Gerber
Intracellular compartmentalization and trafficking of molecules plays a critical role in complex and essential cellular processes. In lung cancer and other malignancies, aberrant nucleocytoplasmic transport of tumor suppressor proteins and cell cycle regulators results in tumorigenesis and inactivation of apoptosis. Pharmacologic targeting of this process, termed selective inhibition of nuclear export (SINE), has demonstrated anti-tumor efficacy in preclinical models and human clinical trials. Exportin-1 (XPO1)-which serves as the sole exporter of several tumor suppressor proteins and cell cycle regulators, including retinoblastoma (Rb), adenomatous polyposis coli (APC), p53, p73, p21, p27, FOXO, STAT3, IKB, topoisomerase II and PAR-4-is the principal focus of SINE drug development...
June 21, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28647671/use-of-oncogenic-driver-mutations-in-staging-of-multiple-primary-lung-carcinomas-a-single-center-experience
#7
Ramsey Asmar, Joshua R Sonett, Gopal Singh, Mahesh M Mansukhani, Alain C Borczuk
PURPOSE: The staging of multiple pulmonary adenocarcinomas requires the distinction of intrapulmonary metastasis (IPM) from multiple primary lung cancers (MPLC). This can be challenging in some patients, and the addition of data from oncogenic driver mutations in these tumors may be helpful in this determination. PROCEDURES: As a proof of principle, molecular driver results from primary tumors and their metastases in 45 patients were compared (cohort 1). Then, 69 patients with a total of 154 synchronous or metachronous lung carcinomas were identified, with pathologic findings compared to oncogenic driver mutation...
June 21, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28634123/clinical-utility-of-chromosomal-aneusomy-in-individuals-at-high-risk-of-lung-cancer
#8
Anna E Barón, Severine Kako, William J Feser, Heather Malinowski, Daniel Merrick, Kavita Garg, Stephen Malkoski, Shannon Pretzel, Jill M Siegfried, Wilbur A Franklin, York Miller, Holly J Wolf, Marileila Varella-Garcia
INTRODUCTION: Low dose CT screening for lung cancer has a high false positive rate with frequent discovery of indeterminate pulmonary nodules. Noninvasive biomarkers are needed to reduce false positives and improve risk stratification. A retrospective longitudinal evaluation was performed to assess chromosomal aneusomy in sputum via fluorescence in situ hybridization (CA-FISH) in four nested case-control studies. METHODS: ROC analysis resulted in two grouped cohorts: High Risk (CO High Risk and CO Nodule; 68 Cases, 69 controls) and Screening (ACRIN/NLST and PLuSS; 97 Cases, 185 controls)...
June 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28629896/randomized-phase-ii-study-of-preoperative-chemoradiotherapy-panitumumab-followed-by-consolidation-chemotherapy-in-potentially-operable-locally-advanced-stage-iiia-n2-non-small-cell-lung-cancer-nrg-oncology-rtog-0839
#9
Martin J Edelman, Chen Hu, Quynh-Thu Le, Jessica S Donington, Warren D D'Souza, Adam P Dicker, Billy W Loo, Elizabeth M Gore, Gregory M M Videtic, Nathaniel R Evans, Joseph W Leach, Maximilian Diehn, Steven J Feigenberg, Yuhchyau Chen, Rebecca Paulus, Jeffrey D Bradley
INTRODUCTION: Multimodality therapy has curative potential in locally advanced non-small cell lung cancer (LASCLC). Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology RTOG 0229 demonstrated the feasibility and efficacy of combining full dose radiation (61.2Gy) with chemotherapy followed by resection and chemotherapy. Based upon that experience and evidence that epidermal growth factor receptor (EGFR) antibodies are radiosensitizing, we explored adding panitumumab to CRT followed by resection and consolidation chemotherapy in LANSCLC with a primary endpoint of MNS...
June 16, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28629895/tumour-suppressor-micrornas-contribute-to-the-regulation-of-pd-l1-expression-in-malignant-pleural-mesothelioma
#10
Steven C Kao, Yuen Yee Cheng, Marissa Williams, Michaela B Kirschner, Jason Madore, Trina Lum, Kadir H Sarun, Anthony Linton, Brian McCaughan, Sonja Klebe, Nico van Zandwijk, Richard A Scolyer, Michael J Boyer, Wendy A Cooper, Glen Reid
INTRODUCTION: The upregulation of PD-L1 is found in many cancers and contributes to the evasion of the host's immune defence. In malignant pleural mesothelioma (MPM), PD-L1 expression is associated with non-epithelioid histological subtype and poor prognosis, but the pathways involved in the control of PD-L1 expression in MPM are poorly understood. To address one possible means of PD-L1 regulation we investigated the relationship between dysregulated microRNA levels and PD-L1 expression...
June 16, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28624467/comprehensive-analysis-of-egfr-mutant-abundance-and-its-effect-on-efficacy-of-egfr-tkis-in-advanced-nsclc-with-egfr-mutations
#11
Xuefei Li, Weijing Cai, Guohua Yang, Chunxia Su, Shengxiang Ren, Chao Zhao, Rongjun Hu, Xiaoxia Chen, Guanghui Gao, Zhiwei Guo, Wei Li, Caicun Zhou, Fred R Hirsch
BACKGROUND: It is not enough sensitive to use a qualitative detection method with sensitivity of 1% to determine EGFR status in advanced NSCLC and guide precise therapy in clinical practice. OBJECTIVE: To explore the relationship between the abundance of EGFR mutations and efficacy of EGFR-TKIs. METHODS: We used ARMS plus (ARMS+) to quantitatively evaluate the abundance of EGFR mutations in 201 advanced NSCLC patients. A cut-off value of the abundance of EGFR mutations was determined by ROC analysis in training group and was validated in validation group...
June 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28624466/resectable-clinical-n2-non-small-cell-lung-cancer-what-is-the-optimal-treatment-strategy-an-update-by-the-british-thoracic-society-lung-cancer-specialist-advisory-group
#12
Matthew Evison, Amelia Clive, Lianne Castle, Helen Powell, Rachel Thomas, Robert Buttery, Vidan Masani, Susan Harden, Doug West, Ian Woolhouse
Patients and clinicians are faced with uncertainty on the optimal treatment strategy for potentially resectable non-small cell lung cancer where there is clinical evidence of involvement of the ipsilateral mediastinum. Randomised controlled trials and meta-analyses have failed to demonstrate superiority of one bimodality strategy over another (chemotherapy plus surgery versus chemotherapy plus radiotherapy). One trial of trimodality treatment with chemotherapy, radiotherapy and surgery demonstrated an improvement in progression-free, but not overall, survival versus chemotherapy and radiotherapy...
June 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28627462/clinical-and-pathological-staging-validation-in-the-eighth-edition-of-tnm-classification-for-lung-cancer-correlation-between-solid-size-on-thin-section-computed-tomography-and-invasive-size-in-pathological-findings-in-the-new-t-classification
#13
Keiju Aokage, Tomohiro Miyoshi, Genichiro Ishii, Masahiro Kusumoto, Shogo Nomura, Shinya Katsumata, Keigo Sekihara, Tomoyuki Hishida, Masahiro Tsuboi
INTRODUCTION: The aim of this study was to validate the new 8th edition of the tumor-node-metastasis (TNM) classification and to elucidate whether radiological solid size corresponds to pathological invasive size incorporated in this T factor. METHODS: We analyzed the data of 1792 patients who underwent complete resection from 2003 to 2011 at the National Cancer Center Hospital East, Japan. We re-evaluated preoperative thin-sliced computed tomography (TSCT) to determine solid size and pathological invasive size using the 3rd edition of the WHO classification and reclassified them according to the new TNM classification...
June 13, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28611011/application-of-plasma-genotyping-technologies-in-non-small-cell-lung-cancer-a-practical-review
#14
REVIEW
Adrian G Sacher, Kimberly M Komatsubara, Geoffrey R Oxnard
The rational treatment of metastatic NSCLC hinges upon the timely detection of potentially targetable genomic alterations in order to guide therapy. Recent advances in highly sensitive genotyping technologies have allowed for the development of novel plasma genotyping assays which are capable of noninvasively detecting targetable alterations in plasma cell-free DNA without reliance on traditional tissue genotyping. The rapid development of plasma genotyping has led to an explosion in the number of assay platforms available from both commercial and laboratory sources...
June 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28611010/cases-of-alk-rearranged-lung-cancer-with-5-year-progression-free-survival-with-crizotinib-as-initial-precision-therapy
#15
Deepa Rangachari, Xiuning Le, Meghan Shea, Mark S Huberman, Paul A VanderLaan, Susumu S Kobayashi, Daniel B Costa
No abstract text is available yet for this article.
June 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28599887/phase-i-trial-of-cediranib-in-combination-with-cisplatin-and-pemetrexed-in-chemo-naive-patients-with-unresectable-malignant-pleural-mesothelioma-swog-s0905
#16
Anne S Tsao, James Moon, Ignacio I Wistuba, Nicholas J Vogelzang, Gregory P Kalemkerian, Mary W Redman, David R Gandara, Karen Kelly
BACKGROUND: In malignant pleural mesothelioma (MPM), targeting angiogenesis, with cediranib, a vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) inhibitor, may have therapeutic potential. METHODS: S0905 phase I combined cediranib (2 dose cohorts 30 mg and 20 mg daily) with cisplatin-pemetrexed for 6 cycles followed by maintenance cediranib in unresectable chemo-naïve MPM patients of any histologic subtype. The primary endpoint established the MTD in combination with cisplatin-pemetrexed in a dose de-escalation schema...
June 6, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28583587/management-of-multifocal-lung-cancer-results-of-a-survey
#17
Konstantinos Leventakos, Tobias Peikert, David Midthun, Julian R Molina, Shanda Blackmon, Francis C Nichols, Yolanda Garces, Christopher L Hallemeier, Stephen J Murphy, George Vasmatzis, Sarah L Kratz, William P Holland, Charles F Thomas, John J Mullon, K Robert Shen, Stephen D Cassivi, Randolph S Marks, Marie Christine Aubry, Alex A Adjei, Ping Yang, Mark S Allen, Eric S Edell, Dennis Wigle, Aaron S Mansfield
INTRODUCTION: Multifocal lung cancer (MFLC) is an increasingly common clinical scenario but there is lack of high-level evidence for its optimal treatment. Thus, we surveyed members of the interdisciplinary International Association for the Study of Lung Cancer (IASLC) on their therapeutic approaches and analyzed the resultant practice patterns. METHODS: We described the clinical scenario of an otherwise healthy 60 years old man with bilateral pulmonary nodules and asked the 6373 IASLC members whether they would recommend surgery, and if so, the extent of surgery...
June 2, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28576747/brief-report-long-term-outcome-of-surgery-or-stereotactic-radiotherapy-for-lung-oligometastases
#18
Joyce E Lodeweges, Theo J Klinkenberg, Jan F Ubbels, Harry J M Groen, Johannes A Langendijk, Joachim Widder
Local treatment for pulmonary oligometastases (one to five lesions) employing metastasectomy or stereotactic ablative radiotherapy (SABR) was investigated in a cohort having received multidisciplinary tumour-board-based treatment decisions. First choice of treatment was surgery, SABR was recommended in case of clinical adverse factors. Propensity-score adjusted and unadjusted overall survival (OS) was the primary endpoint, local control and time-to-failure of a local-only treatment strategy were also analysed...
May 30, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28576746/a-higher-proportion-of-the-egfr-t790m-mutation-may-contribute-to-the-better-survival-of-patients-with-exon-19-deletions-compared-with-those-with-l858r
#19
E-E Ke, Qing Zhou, Qiu-Yi Zhang, Jian Su, Zhi-Hong Chen, Xu-Chao Zhang, Chong-Rui Xu, Jin-Ji Yang, Hai-Yan Tu, Hong-Hong Yan, Yi-Chen Zhang, Fei-Yu Niu, Yi-Long Wu
INTRODUCTION: Increasing evidence has demonstrated that exon 19 deletions (Del19) and L858R mutation in EGFR have different prognostic and predictive roles in non-small-cell lung cancer (NSCLC). We aimed to investigate whether these 2 mutations produced differences in resistance mechanisms to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). METHODS: Consecutive patients with advanced EGFR-mutant NSCLC who acquired resistance to EGFR-TKIs and underwent post-progression biopsies were enrolled...
May 30, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28576745/lung-adenocarcinoma-manifesting-as-pure-ground-glass-nodules-correlating-ct-size-volume-density-and-roundness-with-histopathologic-invasion-and-size
#20
Benedikt H Heidinger, Kevin R Anderson, Ursula Nemec, Daniel B Costa, Sidhu P Gangadharan, Paul A VanderLaan, Alexander A Bankier
HYPOTHESIS: To quantify the relation between computed tomography (CT) size, volume, density, and roundness of lung adenocarcinomas (AC) manifesting as pure ground glass nodules (pGGNs) on CT, and to correlate these parameters with histologic features of invasiveness. METHODS: From 2005 to 2015, 63 ACs manifesting as pGGNs on CT were surgically resected at our institution. CT size was measured, and roundness, volumes and densities were computed. CT parameters were correlated to age and gender, as well as to size and number of invasive foci, and to histologic AC subcategories...
May 30, 2017: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"